Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onalespib - Astex Pharmaceuticals

Next Previous
X
Search
Drug Profile

Onalespib - Astex Pharmaceuticals

Alternative Names: AT-13387; AT-13387X

Latest Information Update: 24 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics
  • Developer Astex Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Benzamides; Isoindoles; Ketones; Piperazines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • No development reported Gastrointestinal stromal tumours; Malignant melanoma; Prostate cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 05 Apr 2024 Efficacy and adverse event data from a phase I trial in Triple-negative Breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 26 Oct 2022 National Cancer Institute terminates a phase I trial in Triple negative Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) due to drug supply issue (NCT02474173)
  • 28 Jun 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top